Mild Lung Restriction in Breast Cancer Patients After Hypofractionated and Conventional Radiation Therapy: A 3-Year Follow-Up.
OBJECTIVE
To assess the effect of radiation therapy on lung function over the course of 3 years.


METHODS
Evolution of restrictive and obstructive lung function parameters was investigated in 108 breast cancer participants in a randomized, controlled trial comparing conventional radiation therapy (CR) and hypofractionated tomotherapy (TT) (age at inclusion ranging 32-81 years). Spirometry, plethysmography, and hemoglobin-corrected diffusing capacity were assessed at baseline and after 3 months and 1, 2, and 3 years. Natural aging was accounted for by considering all lung function parameters in terms of percent predicted values using the most recent reference values for women aged up to 80 years.


RESULTS
In the patients with negligible history of respiratory disease or smoking (n=77), the greatest rate of functional decline was observed during the initial 3 months, this acute decrease being more marked in the CR versus the TT arm. During the remainder of the 3-year follow-up period, values (in terms of percent predicted) were maintained (diffusing capacity) or continued to decline at a slower rate (forced vital capacity). However, the average decline of the restrictive lung function parameters over a 3-year period did not exceed 9% predicted in either the TT or the CR arm. Obstructive lung function parameters remained unaffected throughout. Including also the 31 patients with a history of respiratory disease or more than 10 pack-years showed a very similar restrictive pattern.


CONCLUSIONS
In women with breast cancer, both conventional radiation therapy and hypofractionated tomotherapy induce small but consistent restrictive lung patterns over the course of a 3-year period, irrespective of baseline respiratory status or smoking history. The fastest rate of lung function decline generally occurred in the first 3 months.
Respiratory Division, University Hospital UZ Brussel, Brussels, Belgium. Electronic address: sylvia.verbanck@uzbrussel.be.
Sylvia
S
Verbanck
Respiratory Division, University Hospital UZ Brussel, Brussels, Belgium.
Shane
S
Hanon
Respiratory Division, University Hospital UZ Brussel, Brussels, Belgium.
Daniel
D
Schuermans
Department of Radiotherapy, University Hospital UZ Brussel, Brussels, Belgium.
Hilde
H
Van Parijs
Department of Radiotherapy, University Hospital UZ Brussel, Brussels, Belgium.
Vincent
V
Vinh-Hung
Department of Radiotherapy, University Hospital UZ Brussel, Brussels, Belgium.
Geertje
G
Miedema
Department of Radiotherapy, University Hospital UZ Brussel, Brussels, Belgium.
Dirk
D
Verellen
Department of Radiotherapy, University Hospital UZ Brussel, Brussels, Belgium.
Guy
G
Storme
Department of Senology and Oncologic Surgery, University Hospital UZ Brussel, Brussels, Belgium.
Christel
C
Fontaine
Department of Senology and Oncologic Surgery, University Hospital UZ Brussel, Brussels, Belgium.
Jan
J
Lamote
Department of Radiotherapy, University Hospital UZ Brussel, Brussels, Belgium.
Mark
M
De Ridder
Respiratory Division, University Hospital UZ Brussel, Brussels, Belgium.
Walter
W
Vincken
D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D001530:Belgium / Q000453:epidemiology; D001943:Breast Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000532:radiotherapy*; D015984:Causality; D003131:Combined Modality Therapy / Q000706:statistics & numerical data; D015897:Comorbidity; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D008173:Lung Diseases, Obstructive / Q000175:diagnosis / Q000453:epidemiology*; D008875:Middle Aged; D015995:Prevalence; D000069473:Radiation Dose Hypofractionation; D017564:Radiation Pneumonitis / Q000175:diagnosis / Q000453:epidemiology*; D020266:Radiotherapy, Conformal / Q000706:statistics & numerical data*; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology; D016896:Treatment Outcome